Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Daptomycin
70
CHF
CHF 70.00
In stock
AG-CN2-0542-M02525 mgCHF 70.00
AG-CN2-0542-M100100 mgCHF 190.00
Product Details | |
---|---|
Synonyms | LY146032; Dapcin; Cubicin; Cidecin |
Product Type | Chemical |
Properties | |
Formula |
C72H101N17O26 |
MW | 1620.7 |
CAS | 103060-53-3 |
RTECS | HB5626000 |
Source/Host Chemicals | Isolated from Streptomyces sp. |
Purity Chemicals | ≥95% (HPLC) |
Appearance | Off-white to pale yellow powder. |
Solubility | Soluble in water (25mg/ml), DMSO (50mg/ml) or methanol (5mg/ml). |
Identity | Determined by 1H-NMR. |
InChi Key | DOAKLVKFURWEDJ-RWDRXURGSA-N |
Smiles | O=C(O[C@H](C)[C@H](NC([C@H](CC(O)=O)NC([C@@H](NC([C@@H](NC(CCCCCCCCC)=O)CC1=CNC2=C1C=CC=C2)=O)CC(N)=O)=O)=O)C(NC3)=O)[C@H](CC(C4=C(N)C=CC=C4)=O)NC([C@@H](NC([C@@H](CO)NC(CNC([C@H](CC(O)=O)NC([C@@H](C)NC([C@H](CC(O)=O)NC([C@@H](NC3=O)CCCN)=O)=O)=O)=O)=O)=O)[C@H](C)CC(O)=O)=O |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Keep cool and dry. |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
- Daptomycin, a naturally occurring cyclic lipopeptide, is a calcium-dependent antibiotic.
- It exhibits potent bacteriocidal activity against most Gram-positive bacteria in vitro and in vivo, including antibiotic-resistant strains such as MRSA and VRE.
- Daptomycin disrupts the bacterial plasma membrane function, which results in membrane depolarization consequently leading to inhibition of protein, DNA and RNA synthesis, essential for cell division and cell wall synthesis.
Product References
- In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile: A. Bartoloni, et al.; J. Antimicrob. Chemother. 26, 627 (1990)
- Development of daptomycin for Gram-positive infections: F.P. Tally & M.F. DeBruin; J. Antimicrob. Chemother. 46, 523 (2000)
- Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin; D. Jung, et al.; Chem. Biol. 11, 949 (2004)
- Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections: J.N. Steenbergen, et al.; J. Antimicrob. Chemother. 55, 283 (2005)
- The action mechanism of daptomycin: S.C. Taylor & M. Palmer; Bioorg. Med. Chem. 24, 6253 (2016) (Review)
- More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin: D.A. Gray & M. Wenzel; Antibiotics 9, 17 (2020) (Review)
- DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides: H.W. Huang; Biochim. Biophys. Acta Biomembr. 1862, 183395 (2020) (Review)
- The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane: A. Pokorny & P.F. Almeida; J. Membr. Biol. 254, 97 (2021) (Review)